Sequential use of targeted agents in the treatment of renal cell carcinoma

Critical Reviews in Oncology/Hematology

Volumn 77, Issue 1, 2011, Pages 48-62

  Hutson, Thomas E ^a   Bukowski, Ronald M ^b   Cowey, C Lance ^a   Figlin, Robert ^c   Escudier, Bernard ^d   Sternberg, Cora N ^e  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Everolimus; MTOR inhibitor; Pazopanib; Renal cell carcinoma; Sequential therapy; Sorafenib; Sunitinib; Tyrosine kinase inhibitor

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; AXITINIB; BEVACIZUMAB; CYTOKINE; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; INTERFERON; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; VASCULOTROPIN INHIBITOR;

ANTINEOPLASTIC ACTIVITY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CARDIOTOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPNEA; EVIDENCE BASED MEDICINE; FATIGUE; HAIR COLOR; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY CANCER; KIDNEY CARCINOMA; MOLECULARLY TARGETED THERAPY; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMONIA; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; STOMATITIS;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; CYTOKINES; DRUG RESISTANCE, NEOPLASM; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78650306863     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.07.018     Document Type: Review

References (104)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55(2):74-108.
2. Garcia J.A., Rini B.I. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin 2007, 57(2):112-125.
3. Motzer R.J., Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000, 163(2):408-417.
4. Rini B.I., Campbell S.C., Escudier B. Renal cell carcinoma. Lancet 2009, 373(9669):1119-1132.
5. McDermott D.F., Regan M.M., Clark J.I., Flaherty L.E., Weiss G.R., Logan T.F., et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005, 23(1):133-141.
6. Yang J.C., Sherry R.M., Steinberg S.M., Topalian S.L., Schwartzentruber D.J., Hwu P., et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003, 21(16):3127-3132.
7. Kim W.Y., Kaelin W.G. Role of VHL gene mutation in human cancer. J Clin Oncol 2004, 22(24):4991-5004.
8. Rini B.I., Atkins M.B. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009, 10:992-1000.
9. Motzer R.J., Rini B.I., Bukowski R.M., Curti B.D., George D.J., Hudes G.R., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006, 295(21):2516-2524.
10. Kumar R., Knick V.B., Rudolph S.K., Johnson J.H., Crosby R.M., Crouthamel M., et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007, 6(7):2012-2021.
11. Sternberg C.N., Davis I.D., Mardiak J., Szczylik C., Lee E., Wagstaff J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28(6):1061-1068.
12. Hutson T.E., Davis I.D., Machiels J.P., De Souza P.I., Rottey S., Hong B.F., et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 28(3):475-480.
13. Escudier B., Pluzanska A., Koralewski P., Ravaud A., Bracarda S., Szczylik C., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370(9605):2103-2111.
14. Nexavar® (sorafenib) [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc. (FDA); 2008.
15. Nexavar® (sorafenib) [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc. (EMEA); 2006.
16. Sonpavde G., Hutson T.E., Rini B.I. Axitinib for renal cell carcinoma. Expert Opin Investig Drugs 2008, 17(5):741-748.
17. Albert D.H., Tapang P., Magoc T.J., Pease L.J., Reuter D.R., Wei R.Q., et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 2006, 5:995-1006.
18. Bhargava P., Esteves B., Nosov D.A., Lipatov O.N., Lyulko A.A., Anischenko A.A., et al. Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC) [abstract]. J Clin Oncol 2009, 27(15s). [Abstract 5032].
19. Nakamura K., Taguchi E., Miura T., Yamamoto A., Takahashi K., Bichat F., et al. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res 2006, 66(18):9134-9142.
20. Tannir N., Wong Y., Kollmannsberger C., Ernstoff M.S., Perry D.J., Appleman L.J., et al. Phase II trial of ABT-869 in advanced renal cell cancer (RCC) after sunitinib failure: efficacy and safety results [abstract]. J Clin Oncol 2009, 27(15s). [Abstract 5036].
21. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004, 18(16):1926-1945.
22. Thomas G.V., Tran C., Mellinghoff I.K., Welsbie D.S., Chan E., Fueger B., et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006, 12(1):122-127.
23. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356(22):2271-2281.
24. Motzer R.J., Escudier B., Oudard S., Hutson T.E., Porta C., Bracarda S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
25. Gills J.J., Dennis P.A. Perifosine: update on a novel AKT inhibitor. Curr Oncol Rep 2009, 11(2):102-110.
26. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-216.
27. Janne P.A., Gray N., Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov 2009, 8:709-723.
28. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008, 8(8):592-603.
29. Escudier B., Chevreau C., Lasset C., Douillard J.Y., Ravaud A., Fabbro M., et al. Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérapie. J Clin Oncol 1999, 17(7):2039-2043.
30. Escudier B., Eisen T., Stadler W.M., Szczylik W.M., Oudard S., Siebels, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356(2):125-134.
31. Escudier B., Eisen T., Stadler W.M., Szczylik W.M., Oudard S., Staehler M., et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III Treatment Approaches in Renal cancer Global Evaluation Trial. J Clin Oncol 2009, 27(20):3312-3318.
32. Negrier S, Jäger E, Porta C, McDermott D, Moore M, Bellmunt J, et al. Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET. Med Oncol 2009 [Epub ahead of print]. doi:10.1007/s12032-009-9303-z.
33. Hutson T.E., Davis I.D., Machiels J.P., De Souza P.L., Hong B.F., Rottey R., et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): interim results of a phase II randomized discontinuation trial (RDT) [abstract]. J Clin Oncol 2007, 25(18s). [Abstract 5031].
34. Motzer R.J., Michaelson M.D., Rosenberg J., Bukowski R.M., Curti B.D., George D.J., et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol 2007, 178(5):1883-1887.
35. Escudier B., Roigas J., Gillessen S., Harmenberg U., Srinivas S., Mulder S.F., et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2009, 27(25):4068-4075.
36. Cho D.C., Puzanov I., Regan M.M., Schwarzberg T., Seery V., Lee M.Y., et al. Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. J Immunother 2009, 32(2):181-185.
37. Vickers M.M., Choueiri T.K., Rogers M., Percy A., Finch D., Zama I., et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology 2010, 10.1016/j.urology.2009.12.031.
38. Sablin M.P., Negrier S., Ravaud A., Oudard S., Balleyguier C., Gautier J., et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 2009, 182:29-34.
39. Dudek A.Z., Zolnierek J., Dham A., Lindgren B.R., Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009, 115(1):61-67.
40. Eichelberg C., Heuer R., Chun F.K., Hinrichs K., Zacharias M., Huland H., et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol 2008, 54(6):1373-1378.
41. Porta C., Procopio G., Sabbatini R., Bearz A., Chiappino I., Imariso I., et al. Retrospective analysis of the sequential use of sorafenib and sunitinib in patients with advanced renal cell carcinoma (RCC) [abstract]. Eur J Urol. 2009, 8(Suppl. 4):183. [Abstract 252].
42. Zimmerman K., Schmittel A., Steiner U., Asemissen A.M., Knoedler M., Thiel E., et al. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 2009, 76(5):350-354.
43. Rini B.I., Michaelson M.D., Rosenberg J.E., Bukowski R.M., Sosman J.A., Stadler W.M., et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008, 26(22):3743-3748.
44. Escudier B., Bellmunt J., Negrier S., Bajetta E., Melichar B., Bracarda, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010, 28(13):2137-2143.
45. Rini B.I., Halabi S., Rosenberg J.E., Stadler W.M., Vaena D.A., Ou S.S., et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008, 26(33):5422-5428.
46. Dutcher J.P., Wilding G., Hudes G.R., Stadler W.M., Kim S., Tarazi J.C., et al. Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone [abstract]. J Clin Oncol 2008, 26(Suppl. 20). [Abstract 5127].
47. Rini B.I., Wilding G., Hudes G., Stadler W.M., Kim S., Tarazi J.C., et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009, 27(27):4462-4468.
48. Atkins M.B., Bukowski R.M., Escudier B., Figlin R.A., Hudes G.H., Kaelin W.G., et al. Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference. Cancer 2009, 115(Suppl. 10):2247-2251.
49. Huang D., Ding Y., Zhou M., Rini b., Petillo D., Qian C.N., et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 2010, 70(3):1063-1071.
50. Hutson T.E., Figlin R. Novel therapeutics for metastatic renal cell carcinoma. Cancer 2009, 115(Suppl. 10):2361-2367.
51. Jac J., Amato R.J., Giessinger S., Saxena S., Willis J.P. A phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic renal cell carcinoma which has progressed on tyrosine kinase inhibition therapy [abstract]. J Clin Oncol 2008, 26(Suppl.):5113.
52. Kay A, Motzer R, Figlin R, Escudier B, Oudard S, Porta C, et al. Updated data from a phase III randomized trial of everolimus (RAD001) versus PBO in metastatic renal cell carcinoma (mRCC) [abstract]. 2009 Genitourinary Cancers Symposium. Orlando, FL, February 26-28; 2009 [Abstract 278].
53. Schwandt A, Wood L, Bukowski RM, Elson P, Garcia JA, Gilligan T, et al. Temsirolimus in metastatic renal cell carcinoma: safety and efficacy in patients previously treated with VEGF-targeted therapy [abstract]. 2009 Genitourinary Cancers Symposium. Orlando, FL, February 26-28; 2009 [Abstract 293].
54. Gerullis H., Bergman L., Maute L., Ecke T.H., Eimer C., Bagner J.W., et al. Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma. Med Oncol 2010, 27(2):373-378.
55. Garcia J.A., Danielpour D. Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther 2008, 7(6):1347-1354.
56. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006, 22:159-168.
57. Rini B.I., Halabi S., Rosenberg J.E., Stadler W.M., Vaena D.A., Archer L., et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010, 28(13):2137-2143.
58. Sosman J.A., Flaherty K.T., Atkins M.B., McDermott D.F., Rothenberg M.L., Vermeulen W.L., et al. Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC) [abstract]. J Clin Oncol 2008, 26(Suppl.):5011.
59. Gollob J.A., Rathmell W.K., Richmond T.M., Marino C.B., Miller E.K., Grigson G., et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 2007, 25(22):3288-3295.
60. Hainsworth J.D., Spigel D.R., Burris H.A., Waterhouse D., Clark B.L., Whorf R. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 2010, 28:2131-2136.
61. Merchan J.R., Pitot H.C., Qin R., Liu G., Fitch T.R., Picus J., et al. Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): safety and activity of RKI refractory RCC patients [abstract]. J Clin Oncol 2009, 27(Suppl. 15). [Abstract 5039].
62. Kroog G.S., Feldman D.R., Kondagunta G.V., Ginsberg M.S., Fischer P.M., Trinos M.J., et al. Phase I trial of RAD001 (everolimus) plus sunitinib in patients with metastatic renal cell carcinoma [abstract]. J Clin Oncol 2009, 27(15s). [Abstract 5037].
63. Patel P.H., Senico P.L., Curiel R.E., Motzer R.J. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2009, 7(1):24-27.
64. Harzstark A.L., Rosenberg J.E., Weinberg V.K., Sun J., Ryan C.J., Lin A.M., et al. A phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma [abstract]. J Clin Oncol 2009, 27(15s). [Abstract 5104].
65. Patnaik A., Ricart A., Cooper J., Papadopoulos K., Beeram M., Mita C., et al. A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus, an mTOR inhibitor in patients with advanced solid malignancies [abstract]. J Clin Oncol 2007, 25(18s). [Abstract 3512].
66. Escudier B.J., Negrier S., Gravis G., Chevreau C., Delva R., Bay J., et al. Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial [abstract]. J Clin Oncol 2010, 28(15s). [Abstract 4516].
67. Grothey A., Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005, 23:9441-9442.
68. Chu T.F., Rupnick M.A., Kerkela R., Dallabrida S.M., Zurakowski D., Nguyen L., et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007, 370(9604):2011-2019.
69. Khakoo A.Y., Kassiotis C.M., Tannir N., Plana J.C., Halushka M., Bickford C., et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 2008, 112(11):2500-2508.
70. Schmidinger M., Zielinski C.C., Vogl U.M., Bojic A., Bojic M., Schukro C., et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008, 26(32):5204-5212.
71. Telli M.L., Witteles R.M., Fisher G.A., Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 2008, 19(9):1613-1618.
72. Veronese M.L., Mosenkis A., Flaherty K.T., Gallagher M., Stevenson J.P., Townsend R.R., et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006, 24(9):1363-1369.
73. Wu S., Chen J.J., Kudelka A., Lu J., Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 2008, 9(2):117-123.
74. Bellmunt J., Negrier S., Escudier B., Awada A., Aapro M. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG taskforce. Crit Rev Oncol Hematol 2009, 69:64-72.
75. Hutson T.E., Figlin R.A., Kuhn J.G., Motzer R.J. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008, 13(10):1084-1096.
76. Josephs D.H., Hutson T.E., Pickering L.M., Larkin J.M., Choueiri T.K., Patel T., et al. Efficacy and toxicity of sunitinib in metastatic renal cell carcinoma (mRCC) with severe renal impairment or on haemodialysis [abstract]. J Clin Oncol 2009, 27(15s). [Abstract 5109].
77. Hutson TE. Therapy re-challenge. Eighth International Kidney Cancer Symposium. Chicago, IL, September 25; 2009.
78. Rini BI, Hutson TE, Elson P, Heng DY, Knox JJ, Michaelson D, et al. Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma [abstract]. Genitourinary Cancers Symposium. San Francisco, CA, March 5; 2010 [Abstract 319].
79. Escudier B., Szczylik C., Hutson T.E., Demkow T., Staehler M., Rolland F., et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27(8):1280-1289.
80. Ratain M.J., Eckhardt S.G. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol 2004, 22(22):4442-4445.
81. Blanke C.D., Demetri G.D., von Mehren M., Heinrich M.C., Eisenberg B., Fletcher J.A., et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008, 26(4):620-625.
82. Rini B.I. Metastatic renal cell carcinoma: many treatment options, one patient. J Clin Oncol 2009, 27(19):3225-3234.
83. Temsirolimus versus sorafenib as second-line therapy in patients with advanced RCC who have failed first-line sunitinib. Available at: Accessed 7/14/2010. http://www.clinicaltrials.gov/.
84. Axitinib (AG 013736) as second line therapy for metastatic renal cell cancer. Available at: Accessed 7/14/2010. http://www.clinicaltrials.gov/.
85. Sequential study to treat renal cell carcinoma. Available at: Accessed 7/14/2010. http://www.clinicaltrials.gov/.
86. An extension treatment protocol for subjects who have participated in a phase 3 study of tivozanib versus sorafenib in renal cell carcinoma. Protocol AV-951-09-301. Available at: Accessed 7/14/2010. http://www.clinicaltrials.gov/.
87. A study to compare tivozanib 9AV-951 to sorafenib in subjects with advanced renal cell carcinoma (TIVO-1). Available at: Accessed 7/14/2010. http://www.clinicaltrials.gov/.
88. Hawkins R., Hong S.J., Ulys A., Rolski J., Hong B., Sternberg C.N. An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2009, 27(15s). [Abstract 5110].
89. Castellano D.E., Sepulveda J., Diaz Padilla I., Coronado C., Holgado E., Garcia Escobar I., et al. Sunitinib therapy for patients with advanced renal cell carcinoma (aRCC): analysis for safety and activity on single institution experience-prolonged overall survival [abstract]. J Clin Oncol 2008, 26(Suppl.). [Abstract 16119].
90. Tamaskar I., Garcia J.A., Elson P., Wood, Mekhail T., Dreicer R., et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008, 179(1):81-86.
91. Di Lorenzo G., Carteni G., Autorino R., Bruni G., Tudini M., Rizzo M., et al. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol 2009, 27(27):4469-4474.
92. Shepard D.R., Rini B.I., Garcia J.A., Hutson T.E., Elson P., Gilligan T., et al. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab [abstract]. J Clin Oncol 2008, 26(Suppl.). [Abstract 5123].
93. Procopio G, Verzoni E, Guadalupi V, Pietrantonio F, Salvioni R, Nicolai N, et al. Sequential use of sorafenib (So) followed by sunitinib (Su) in metastatic renal cell cancer (mRCC): a single-institution experience [abstract]. Genitourinary Cancers Symposium. Orlando, FL, February 26-28; 2009 [Abstract 319].
94. Drabkin H.A., Figlin R.A., Stadler W.M., Hutson T.E., Hajdenberg J., Chu L., et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: safety and efficacy in patients (pts) with prior bevacizumab (BEV) treatment [abstract]. J Clin Oncol 2007, 25(18s). [Abstract 5041].
95. Mancuso A.P., Donato De Paola E., Catalano A., Calabrò F., Messina C., Zivi A., et al. Phase II dose escalation study of sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have had prior treatment with VEGFR-TKI antiangiogenic treatment [abstract]. J Clin Oncol 2009, 27(15s). [Abstract e16027].
96. Shaheen P.E., Rini B.I., Bukowski R.M. Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports. Clin Genitourin Cancer 2006, 5(1):78-81.
97. Rini BI, Hutson TE, Elson P, Garcia JA, Gilligan T, Nemec C, et al. A prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab [abstract]. Genitourinary Cancers Symposium. San Francisco, CA, February 14-16; 2008 [Abstract 346].
98. Hajdenberg J., Oberi S., Cohen N., Kayaleh O., Harding D., Tseng J. Evaluation of VEGF targeted therapy efficacy in mRCC after sorafenib failure or intolerance [abstract]. J Clin Oncol 2007, 25(18s). [Abstract 15517].
99. Sepulveda J., Maroto P., Andres R., Diaz Padilla I., Coronado C., DelaRosa F., et al. Sorafenib as a second-line and sequential therapy for patients with metastatic renal cell carcinoma (mRCC): analysis for safety and activity on sunitinib progressive pts [abstract]. J Clin Oncol 2008, 26(Suppl.). [Abstract 16100].
100. Elfiky AA, Cho DC, McDermott DF, Rosenberg J, Fortner B, Antràs L, et al. Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma. Urol Oncol 2010 [Epub ahead of print. ]. doi:10.1016/j.urolonc.2010.01.008.
101. Richter S., Pfister D., Thüer D., Engelmann U.H., Heidenreich A. Second-line treatment of progressive metastatic renal cell cancer with temsirolimus following first-line therapy with sunitinib or sorafenib. Onkologie 2009, 31:324. [Abstract V684].
102. Schmidinger M., Vogl U.M., Lamm W., Bojic M., Bojic A., Zielinski C.C. Temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma: preliminary results from the Austrian Compassionate Use Program [abstract]. J Clin Oncol 2008, 26(Suppl.). [Abstract 16125].
103. Flaig, TW, Costa L, Breaker K, Schultz M, Crighton F, Kim FJ, et al. Erlotinib with sirolimus for advanced renal cell carcinoma: preliminary efficacy results. ASCO Genitourinary Cancers Symposium. Orlando, FL, February 26-28; 2009.
104. Vogelzang N.J., Hutson T.E., Samlowski W., Somer B., Richey S., Alemany C., et al. Phase II study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx) with a VEGF receptor inhibitor. J Clin Oncol 2009, 27(15s). [Abstract 5034].